Literature DB >> 711323

Protective effect of vaccination against Mycoplasma pulmonis respiratory disease in rats.

G H Cassell, J K Davis.   

Abstract

Intravenous vaccination of rats with either viable or Formalin-inactivated Mycoplasma pulmonis reduced the incidence and severity of lower respiratory tract lesions after intranasal challenge with viable organisms. Intranasal vaccination with killed organisms reduced the severity of rhinitis, but did not affect lesions in any other region of the respiratory tract. The maximum protection against upper tract lesions (rhinitis, otitis, and laryngotracheitis) was provided by intravenous immunization with viable organisms. Dual vaccination (intraperitoneal plus intranasal) with killed organisms provided no significant protection in any segment of the tract. However, these ineffective vaccine regimens did not potentiate the lesions. These results conclusively demonstrate that vaccination of rats against mycoplasma respiratory disease is feasible and also suggest that systemic vaccination may provide greater protection for the lungs than intranasal vaccination, at least when equivalent antigen doses are used.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 711323      PMCID: PMC421959          DOI: 10.1128/iai.21.1.69-75.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Infection and Immunity in Mouse Catarrh.

Authors:  H E Pearson
Journal:  J Bacteriol       Date:  1942-02       Impact factor: 3.490

2.  Immunoprophylaxis of experimental Mycoplasma pneumoniae disease: effect of aerosol particle size and site of deposition of M. pneumoniae on the pattern of respiratory infection, disease, and immunity in hamsters.

Authors:  J V Jemski; C M Hetsko; C M Helms; M B Grizzard; J S Walker; R M Chanock
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

3.  Immunolgic reactivity of the lung. V. Regulatory effects of antibody on the pulmonary immune response to locally administered antigen.

Authors:  G W Hunninghake; A S Fauci
Journal:  J Immunol       Date:  1977-05       Impact factor: 5.422

4.  Immunity and immunopathology in virus infections.

Authors:  A C Allison
Journal:  Ann Inst Pasteur (Paris)       Date:  1972-10

5.  Pathogenicity of Mycoplasma pulmonis in laboratory rats.

Authors:  D F Kohn; B E Kirk
Journal:  Lab Anim Care       Date:  1969-06

Review 6.  Immunity to mycoplasmas causing respiratory diseases in man and animals.

Authors:  P Whittlestone
Journal:  Adv Vet Sci Comp Med       Date:  1976

7.  Immune response of pathogen-free mice inoculated intranasally with Mycoplasma pulmonis.

Authors:  G H Cassell; J R Lindsey; H J Baker
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

8.  Enhancement of natural and experimental respiratory mycoplasmosis in rats by hexamethylphosphoramide.

Authors:  R G Overcash; J R Lindsey; G H Cassel; H J Baker
Journal:  Am J Pathol       Date:  1976-01       Impact factor: 4.307

9.  The role of environmental ammonia in respiratory mycoplasmosis of rats.

Authors:  J R Broderson; J R Lindsey; J E Crawford
Journal:  Am J Pathol       Date:  1976-10       Impact factor: 4.307

10.  Protective effect of vaccines on Mycoplasma pulmonis-induced respiratory disease of mice.

Authors:  G Taylor; C J Howard; R N Gourlay
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

View more
  16 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

2.  Gene transfer in Mycoplasma pulmonis.

Authors:  Amy M Teachman; C Todd French; Huilan Yu; Warren L Simmons; Kevin Dybvig
Journal:  J Bacteriol       Date:  2002-02       Impact factor: 3.490

3.  Interferon gamma and interleukin 4 have contrasting effects on immunopathology and the development of protective adaptive immunity against mycoplasma respiratory disease.

Authors:  Sheetal Bodhankar; Xiangle Sun; Matthew D Woolard; Jerry W Simecka
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

4.  High-frequency variation in Mycoplasma pulmonis colony size.

Authors:  K Dybvig; J W Simecka; H L Watson; G H Cassell
Journal:  J Bacteriol       Date:  1989-09       Impact factor: 3.490

5.  Nonspecific lymphocyte responses in F344 and LEW rats: susceptibility to murine respiratory mycoplasmosis and examination of cellular basis for strain differences.

Authors:  J K Davis; J W Simecka; J S Williamson; S E Ross; M M Juliana; R B Thorp; G H Cassell
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

6.  Adsorption of mycoplasma virus P1 to host cells.

Authors:  K Dybvig; J Alderete; H L Watson; G H Cassell
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

7.  THE MULTIFACETED ROLE OF T CELL-MEDIATED IMMUNITY IN PATHOGENESIS AND RESISTANCE TO MYCOPLASMA RESPIRATORY DISEASE.

Authors:  Nicole A Dobbs; Adam N Odeh; Xiangle Sun; Jerry W Simecka
Journal:  Curr Trends Immunol       Date:  2009

8.  Monoclonal antibodies that inhibit mitogenic activity of Mycoplasma pulmonis.

Authors:  Z Lapidot; R Siman-Tov; Y Naot
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization.

Authors:  Sheetal Bodhankar; Mathew D Woolard; Xiangle Sun; Jerry W Simecka
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

10.  Murine respiratory mycoplasmosis in F344 and LEW rats: evolution of lesions and lung lymphoid cell populations.

Authors:  J K Davis; R B Thorp; P A Maddox; M B Brown; G H Cassell
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.